Physician profile
Anastasios Roumeliotis
NPI 1578192084
$1,205.77
in general payments reported to CMS, 2019-2025
9 companies · $864 in 2025
The $864 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $109 · 2024: $233 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,205.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $409.04 | 2025 | Symplicity G3, Cobalt Dr Mri Surescan, Onyx Frontier |
| Actelion Pharmaceuticals US, INC. | $251.57 | 2024-2025 | Opsumit, Uptravi |
| Bridgebio Pharma, INC. | $140.29 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $121.87 | 2025 | |
| Alnylam Pharmaceuticals INC. | $89.19 | 2024 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $72.80 | 2023-2025 | Breztri, Wainua, Farxiga |
| Pfizer INC. | $58.38 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.90 | 2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $13.73 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anastasios Roumeliotis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.